Polaryx Therapeutics, Inc.
PLYX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002075320
No open-market purchases or sales by Polaryx Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $5.83M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Polaryx Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Polaryx Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Yang Alex Keun Mo | Chief Executive Officer | 24,233,249Indirect | May 28, 2026 | 1 |
| Mstone Partners Healthcare Ltd | Director, 10% Owner | 24,233,249Indirect | May 28, 2026 | 1 |
| Landis G. Michael | Chief Financial Officer | 228,225 | Feb 20, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 28, 2026 (view filing)8:00 PM ET | May 27 | 1 day | Yang Alex Keun Mo and 1 otherChief Executive Officer | PPurchase | +88.5K | $4.07 | +$360.0K | +0.4%24.2M after | |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Landis G. MichaelChief Financial Officer | PPurchase | +2.87K | $2.79 | +$8.00K | +1.3%228.2K after |